Why Novo Nordisk Stock Got Destroyed Today, but Eli ... - The …

Dec 20, 2024 · Bad news for Novo Nordisk (NVO-1.88%) Friday was good news for Eli Lilly (LLY-1.19%) and Viking Therapeutics (VKTX-3.38%), its two main rivals in the field of weight loss drugs. This morning, Novo ...

CouponFollow Extension

88%
OFF

Why Novo Nordisk Stock Got Destroyed Today, But Eli ... - The …

4 weeks from now

fool.com

70%
OFF

Why Novo Nordisk Stock Dipped Today | The Motley Fool

4 weeks from now

Sep 18, 2023 · Novo Nordisk (NVO-1.70%) stock didn't enjoy a good start to this week. The company behind the "it" drugs of the moment, Wegovy -- and, to a lesser extent, Ozempic -- …

fool.com

19%
OFF

Down 19% In 1 Day, Is Novo Nordisk Stock Still A Buy?

4 weeks from now

6 days ago · Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More Down 19% …

fool.com

3%
OFF

Why Novo Nordisk Stock Tumbled By Nearly 3% On Tuesday

4 weeks from now

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that …

yahoo.com

6%
OFF

Why Novo Nordisk Stock Fell While Eli Lilly And Viking …

4 weeks from now

Sep 20, 2024 · Novo Nordisk's stock price declined by nearly 6% on the day, while the two gainers rose 3.4% and 0.7%, respectively. Side effects reported for investigational drug

yahoo.com

7%
OFF

Why Novo Nordisk Stock Is Slipping Today - MSN

4 weeks from now

Jul 2, 2024 · S hares of Novo Nordisk (NYSE: NVO) were slipping 1.7% lower as of 10:57 a.m. ET on Tuesday, after falling as much as 4.4% earlier in the day. The decline came after USA …

msn.com

34%
OFF

3 Stocks That Could Be Monster Winners In 2025 | The Motley Fool

4 weeks from now

3 days ago · Here's why they believe Novo Nordisk (NVO 0.34%), Summit Therapeutics (SMMT-0.25%), and Viking Therapeutics (VKTX 1.18%) could be monster winners for 2025. Novo …

fool.com

7%
OFF

Why Novo Nordisk Stock Is Slipping Today - The Globe And Mail

4 weeks from now

Why Novo Nordisk Stock Is Slipping Today Motley Fool - Tue Jul 2, 10:54AM CDT Shares of Novo Nordisk (NYSE: NVO) were slipping 1.7% lower as of 10:57 a.m. ET on Tuesday, after …

theglobeandmail.com

8%
OFF

Why Novo Nordisk Stock Got Destroyed Today, But Eli Lilly

4 weeks from now

Dec 20, 2024 · As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece. Originally designed to treat patients with …

sharewise.com

88%
OFF

Why Novo Nordisk (NVO) Dipped More Than Broader Market …

4 weeks from now

Novo Nordisk (NVO) closed at $85.73 in the latest trading session, marking a -1.88% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 1.07% for the day ...

msn.com

18%
OFF

Novo Nordisk Stock Plunges 18% In A Week: What Should …

4 weeks from now

Dec 24, 2024 · In the past six months, shares of Novo Nordisk have plunged 39.6% compared with the industry’s decline of 17.7%. The stock has also underperformed the sector and the …

yahoo.com

4%
OFF

Why Novo Nordisk Stock Crushed The Market On Monday

4 weeks from now

Feb 5, 2024 · A major acquisition by its controlling shareholder pushed Novo Nordisk's U.S.-listed shares 4% higher on Monday. As a result of the deal, Novo Nordisk will acquire from that …

nasdaq.com

83%
OFF

Is Now A Good Time To Buy The Dip In Eli Lilly Stock?

4 weeks from now

Dec 21, 2024 · Making headway against the competition: Right now, the biggest names in obesity care are Novo Nordisk's (NVO-17.83%) Wegovy and Lilly's Zepbound. In a recent study, Lilly …

fool.com

88%
OFF

Why Novo Nordisk (NVO) Dipped More Than Broader Market Today

4 weeks from now

1 day ago · Novo Nordisk (NVO) closed at $85.73 in the latest trading session, marking a -1.88% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 1.07% …

nasdaq.com

18%
OFF

Down 18% In 1 Day, Is Viking Therapeutics Stock In ... - The Motley …

4 weeks from now

Dec 21, 2024 · You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our …

fool.com

FAQs about Why Novo Nordisk Stock Got Destroyed Today, but Eli ... - The … Coupon?

Should you buy Novo Nordisk?

The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Popularity has its downsides. ...

Is Novo Nordisk a good pick for long-term investors?

Novo also has a promising late-stage pipeline. Although its valuation is high, with shares trading at 43 times forward earnings, I think Novo Nordisk is still a good pick for long-term investors. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. ...

What did investors expect from Novo Nordisk?

Numerous analysts and investors were expecting a higher figure. For example, Morgan Stanley, an investment bank that tracks the stock, was anticipating at least 30%. Although the results were considered disappointing, investors did not rush for the exits with Novo Nordisk. ...

What happened to Novo Nordisk (NVO)?

Novo Nordisk (NVO) closed at $85.73 in the latest trading session, marking a -1.88% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 1.07% for the day. Meanwhile, the Dow experienced a drop of 0.97%, and the technology-dominated Nasdaq saw a decrease of 1.19%. ...

Why did Novo Nordisk stock plunge 18% in a week?

Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do? Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do? Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its next-generation subcutaneous obesity candidate, CagriSema. ...

What's going on with Novo Nordisk's shares in 2024?

David Jagielski (Novo Nordisk): It's been a tough 2024 for drugmaker Novo Nordisk. Entering this week, its shares were down 14% as the company behind the popular diabetes drug Ozempic has been generating good growth, but that hasn't been enough to win over investors. ...